AF Association
12,861 members15,687 posts

FDA approves new trial of LAA closure device

Another possible improvement in AF treatment.


“The LAA is an important site for AF initiation and persistence, and its exclusion using the Lariat device as an adjunct to conventional ablation could be a major breakthrough in decreasing recurrence in patients with persistent atrial fibrillation,” Dhanunjaya Lakkireddy, MD, FACC, FHRS, professor of medicine and director of the Center for Excellence in AF and Complex Arrhythmias at the University of Kansas Medical Center, said in the release. “The AMAZE trial is rigorously designed and we believe will further validate the mechanical and electrical isolation benefits of the Lariat device, which has the potential to become a standard of care in treating persistent or longstanding persistent atrial fibrillation.”

2 Replies

Trans thorasic key hole surgery? Some good results apparently being seen in LAA occlusion and two part surgical/catheter ablations.


Encouraging news for those in persistant AF.


You may also like...